We are live on
!
Find out more
OMC
OUP Management Company Portfolio holdings
AUM
$44.5M
1-Year Est. Return
55.11%
This Fund
S&P 500
This Quarter
Est. Return
-31.4%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.7M
AUM Growth
-$58.7M
(-45%)
Cap. Flow
-$8.77M
Cap. Flow
% of AUM
-12.08%
Top 10 Holdings %
Top 10 Hldgs %
94.86%
Holding
16
New
–
Increased
–
Reduced
3
Closed
1
Avg Time Held
2
quarters
Top 10 Avg Time Held
1.8
quarters
Top 20 Avg Time Held
2
quarters
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IonQ
IONQ
|
+$6.67M |
| 2 |
Sera Prognostics
SERA
|
+$1.28M |
| 3 |
Evolv Technologies
EVLV
|
+$633K |
| 4 |
Landos Biopharma, Inc. Common Stock
LABP
|
+$195K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.9% |
| 2 | Technology | 8.3% |
| 3 | Industrials | 5.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
| $14.3M | 19.69% |
2,937,615
| – | – |
2021 Q4
2 quarters
|
|
2
PMV Pharmaceuticals
PMVP
$78.6M
| $14.1M | 19.4% |
989,232
| – | – |
2021 Q4
2 quarters
|
|
3
Jade Biosciences
JBIO
$893M
| $9.44M | 12.99% |
17,250
| – | – |
2021 Q4
2 quarters
|
|
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $8.33M | 11.46% |
536,693
| – | – |
2021 Q4
2 quarters
|
|
|
CYT
5
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $7.4M | 10.18% |
2,474,572
| – | – |
2021 Q4
2 quarters
|
|
|
6
IonQ
IONQ
$14.7B
| $6.03M | 8.3% |
1,377,597
-941,922
| -41% | -$6.67M |
2021 Q4
2 quarters
|
|
|
7
Evolv Technologies
EVLV
$792M
| $4.21M | 5.79% |
1,582,721
-238,145
| -13% | -$633K |
2021 Q4
2 quarters
|
|
8
Vor Biopharma
VOR
$1.2B
| $1.86M | 2.56% |
18,736
| – | – |
2021 Q4
2 quarters
|
|
9
Precision BioSciences
DTIL
$179M
| $1.8M | 2.47% |
37,464
| – | – |
2021 Q4
2 quarters
|
|
10
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $1.46M | 2% |
41,028
| – | – |
2021 Q4
2 quarters
|
|
|
11
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $1.17M | 1.62% |
161,276
-21,472
| -12% | -$195K |
2021 Q4
2 quarters
|
|
12
Cartesian Therapeutics
RNAC
$213M
| $1.13M | 1.56% |
28,751
| – | – |
2021 Q4
2 quarters
|
|
13
LENZ Therapeutics
LENZ
$116M
| $1.12M | 1.54% |
58,044
| – | – |
2021 Q4
2 quarters
|
|
14
Spero Therapeutics
SPRO
$70.5M
| $185K | 0.25% |
249,070
| – | – |
2021 Q4
2 quarters
|
|
15
Q32 Bio
QTTB
$264M
| $126K | 0.17% |
3,556
| – | – |
2021 Q4
2 quarters
|
|
|
16
Sera Prognostics
SERA
$82.8M
| – | – |
-337,505
| Closed | -$1.28M | – |
|
Similar funds
JMF
AMC
MCAV
SIP
KXA
WRCAI
MAM
GIA
OUP Management Company's Q2 2022 Portfolio in Review
As of Q2 2022, OUP Management Company held 16 positions worth $72.7M, down 45% from $131M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
OUP Management Company withdrew a net $8.77M in Q2 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Sera Prognostics, an estimated $1.28M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 74% a quarter earlier, followed by Technology and Industrials.
- OUP Management Company's biggest Q2 2022 reduction was IonQ, cutting an estimated $6.67M.
- OUP Management Company fully exited Sera Prognostics in Q2 2022, selling an estimated $1.28M.
- OUP Management Company's ten largest holdings make up 95% of its $72.7M portfolio in Q2 2022.
- OUP Management Company opened 0 new positions and closed 1 in Q2 2022.
- OUP Management Company's portfolio value fell 45% quarter-over-quarter to $72.7M.
Based on OUP Management Company's 13F filing for Q2 2022, filed 19 Jul 2022.